Abstract
Hemorphins are known for their role in the control of blood pressure. Recently, we revealed the positive modulation of the angiotensin II (AngII) type 1 receptor (AT1R) by LVV-hemorphin-7 (LVV-H7) in human embryonic kidney (HEK293) cells. Here, we examined the molecular binding behavior of LVV-H7 on AT1R and its effect on AngII binding using a nanoluciferase-based bioluminescence resonance energy transfer (NanoBRET) assay in HEK293FT cells, as well as molecular docking and molecular dynamics (MD) studies. Saturation and real-time kinetics supported the positive effect of LVV-H7 on the binding of AngII. While the competitive antagonist olmesartan competed with AngII binding, LVV-H7 slightly, but significantly, decreased AngII’s kD by 2.6 fold with no effect on its Bmax. Molecular docking and MD simulations indicated that the binding of LVV-H7 in the intracellular region of AT1R allosterically potentiates AngII binding. LVV-H7 targets residues on intracellular loops 2 and 3 of AT1R, which are known binding sites of allosteric modulators in other GPCRs. Our data demonstrate the allosteric effect of LVV-H7 on AngII binding, which is consistent with the positive modulation of AT1R activity and signaling previously reported. This further supports the pharmacological targeting of AT1R by hemorphins, with implications in vascular and renal physiology.
Highlights
Hemorphins are endogenous hemoglobin-derived peptides implicated in numerous physiological and pathophysiological situations including spatial learning, inflammation, analgesia, and transient hypotension [1,2,3,4,5,6,7]
We examined the effect of LVV-H7 on the previously showedusing a positive allosteric modulation of in activity and binding We of angiotensin II (AngII)
Hemorphins are endogenous bioactive peptides produced during proteolytic cleavage of hemoglobin
Summary
Hemorphins are endogenous hemoglobin-derived peptides implicated in numerous physiological and pathophysiological situations including spatial learning, inflammation, analgesia, and transient hypotension [1,2,3,4,5,6,7]. AngII type canonical Gαq/inositol phosphate pathway of AT1R, as well as on the phosphorylation receptor (AT1R) as a second GPCR to be pharmacologically targeted by the decapeptide of the extracellular signal-regulated-kinases (ERK1/2) [14]. These effects were observed on the ca- with the anti-hypertensive properties of hemorphins through the inhibition of ACE. LVV-H7 to AT1R by cates the complexity of the interplay between hemorphins and the physiological systems using the NanoBRET technology recently developed for hormone-receptor binding in such as the vascular system. NanoBRET technology recently developed for hormone-receptor binding in real-time and live cells [15] as well as molecular docking and long molecular dynamics (MD) simu-
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
